STOCK TITAN

Cingulate (CING) SEC Filings

CING NASDAQ

Cingulate Inc. filings document a clinical-stage biopharmaceutical issuer developing Precision Timed Release™ drug-delivery products, including CTx-1301 for ADHD, alongside its common stock and warrants listed on Nasdaq. Periodic and current reports furnish operating results, business updates, patent notices, FDA-related program disclosures and research-and-development spending context.

The filing record also covers capital-structure actions such as private placements, preferred stock, warrants, unregistered equity issuances, debt exchanges and at-the-market offering agreements. Proxy and 8-K disclosures address shareholder voting matters, Nasdaq rule compliance, board committee composition, officer appointments, employment agreements and other governance events.

Rhea-AI Summary

Cingulate Inc. (CING) reported a $22.9 million net loss for the nine months ended September 30, 2026, versus $16.2 million a year earlier; net cash used in operations was $20.2 million versus $13.6 million. Third-quarter net loss was $7.7 million, compared with $7.3 million. It had $23.2 million in cash and cash equivalents and a $155.3 million accumulated deficit at September 30. Management said it believes its cash will fund operations into mid-2027, while additional funding is needed.

The company disclosed substantial doubt about its ability to continue as a going concern within one year after the financial statements’ issuance. The FDA’s June 1, 2026 Complete Response Letter requested additional Chemistry, Manufacturing and Controls information for CTx-1301 and raised no clinical safety or efficacy concerns. Cingulate expected to resubmit the NDA between December 2026 and January 2027. The current ATM agreement allows up to $100 million in gross stock sales; third-quarter sales under it generated $2.2 million in net proceeds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.79%
Tags
quarterly report
-
Rhea-AI Summary

Cingulate Inc. (CING) amended its at-the-market sales agreement to add Maxim Group LLC as an agent alongside A.G.P. Under the existing agreement, the company may sell common stock from time to time for an aggregate offering price of up to $100 million. Cingulate said it substantially completed manufacturing work addressing FDA chemistry, manufacturing and controls requests for CTx-1301 and expects to resubmit its NDA between December 2026 and January 2027. The June 1, 2026 Complete Response Letter identified CMC information requests and did not identify clinical safety or efficacy concerns.

At September 30, 2026, cash and cash equivalents were approximately $23.2 million and working capital was approximately $18.8 million. Cingulate believes its cash will fund operations into mid-2027 under its current business plan. Third-quarter net loss was $7.7 million, compared with $7.3 million a year earlier; nine-month net loss was $22.9 million, compared with $16.2 million. Nine-month SG&A was $14.2 million, up 116.6% from $6.6 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.79%
Tags
current report
-
Rhea-AI Summary

Cingulate Inc. amended its at-the-market offering of common stock, with an aggregate offering price of up to $100,000,000. Shares may be offered from time to time through or to A.G.P./Alliance Global Partners under the March 24, 2026 sales agreement. The amendment adds Maxim Group LLC as an additional sales agent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.79%
Tags
prospectus
Rhea-AI Summary

Cingulate Inc. expects to resubmit the CTx-1301 New Drug Application between December 2026 and January 2027. The FDA’s June 1, 2026, Complete Response Letter requested additional chemistry, manufacturing and controls information and raised no concerns regarding clinical safety or efficacy.

Cingulate and its contract drug manufacturing organization have substantially completed the requested manufacturing work and are finalizing supporting data and documentation. Subject to FDA approval, the company says commercial launch could begin in the third quarter of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
current report
-
Rhea-AI Summary

Cingulate Inc.'s EVP and CSO Raul R. Silva received a grant of stock options covering 4,293 common shares on September 30, 2026. The options have a $4.95 per-share exercise price and expire September 30, 2036. Silva's reported direct option position following the grant was 4,293 options. The grant was made pursuant to the terms of Dr. Silva's Employment Agreement, as amended.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
insider
-
Rhea-AI Summary

Cingulate Therapeutics LLC, Cingulate Inc.’s wholly owned subsidiary, entered Amendment No. 2 to the employment agreement with Matthew N. Brams, Executive Vice President and Chief Medical Officer, effective September 30, 2026. The amendment extended the Trial Period for Mr. Brams’ full-time employment from September 30, 2026, to December 31, 2026. The employment agreement was effective January 1, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
current report
Rhea-AI Summary

Cingulate Inc., a pre‑revenue biopharmaceutical company focused on ADHD and anxiety therapies, reported a net loss of $5.9 million for the quarter and $15.2 million for the six months ended June 30 2026, larger than the prior‑year periods. Operating cash outflow was $12.8 million in the first half.

Cash and cash equivalents increased to $28.4 million from $11.0 million at year‑end 2025, driven by a $12.0 million private placement, at‑the‑market issuances and equity sales under a Lincoln Park purchase agreement. Total liabilities fell to $9.6 million, primarily as a prior Streeterville note was extinguished and the Avondale note was partially repaid or exchanged into equity.

The FDA issued a Complete Response Letter for lead ADHD candidate CTx‑1301, requesting additional CMC information but not raising clinical safety or efficacy concerns. Management is working with its CDMO to support NDA resubmission. The company discloses substantial doubt about its ability to continue as a going concern despite current liquidity, and expects to seek additional capital. A new U.S. patent issued in June 2026 protects CTx‑1301 through December 2042.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
quarterly report
-
Rhea-AI Summary

Cingulate Inc. reported second quarter 2026 results and detailed progress on its lead ADHD candidate CTx-1301 and commercialization plans. Cash and cash equivalents were $28.4 million as of June 30 2026, up from $11.0 million at year-end 2025, driven by a $12.0 million private placement and $19.0 million raised via an at-the-market program and a purchase agreement, partially offset by $12.8 million of operating cash use. Working capital rose to $21.6 million, and the company believes this cash will fund operations into mid-2027.

R&D expenses fell to $1.5 million for the quarter, down 44.9% year over year, while SG&A expenses increased to $3.9 million, up 101.5%, reflecting commercial readiness investments. Net loss was $5.9 million for the quarter and $15.2 million for the first half of 2026. Total stockholders’ equity increased to $23.5 million.

Regulatory efforts continue after an FDA Complete Response Letter on June 1 2026 requesting additional CMC information for the CTx-1301 NDA, with no new clinical safety or efficacy concerns cited. Cingulate plans to resubmit the NDA as promptly as practicable, has secured a new U.S. patent protecting CTx-1301 through December 2042, and expanded launch infrastructure through agreements with Prasco, Indegene, and IQVIA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
current report
-
Rhea-AI Summary

Cingulate Inc. announced a leadership and organizational change. On July 17, 2026, the Board of Directors determined to eliminate the position of Chief Legal Officer. As a result, Nilay Patel will no longer serve as an officer of the company, effective August 3, 2026, defined as the Separation Date.

His termination will be treated as a termination without cause under his existing employment agreement with the company. Cingulate stated that it does not intend to hire a replacement for the Chief Legal Officer role, indicating that the responsibilities will be addressed without reinstating this executive position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
current report
Rhea-AI Summary

Cingulate Inc. reported that Chief Executive Officer and director Shane J. Schaffer received two grants of stock options on July 16, 2026. One grant covers 197,650 options and a second covers 97,350 options, each exercisable for common stock at an exercise price of $4.43 per share and expiring on July 16, 2036. The options vest 25% on March 31, 2027, with the remainder vesting in substantially equal monthly installments over the following 36 months. For the 97,350-option grant, even vested options only become exercisable if Cingulate’s NDA for CTx-1301 is approved by the FDA during 2027; if that NDA is not approved during 2027, this option grant, including any vested portion, terminates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
insider

FAQ

How many Cingulate (CING) SEC filings are available on StockTitan?

StockTitan tracks 71 SEC filings for Cingulate (CING), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Cingulate (CING)?

The most recent SEC filing for Cingulate (CING) was filed on November 13, 2026.